



A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3K β/δ , in Patients with Advanced Solid Tumors

Atish D. Choudhury¹, Celestia S. Higano², Johann S. de Bono³, Natalie Cook⁴, Dana E. Rathkopf⁵, Kari B. Wisinski⁶, Juan Martin-Liberal⁷, Mark Linch⁸, Elisabeth I. Heath⁹, Richard D. Baird¹⁰, Javier García-Carbacho¹¹, Miguel Quintela-Fandino¹², Simon T. Barry¹³, Elza C. de Bruin¹³, Steve Colebrook¹³, George Hawkins¹³, Teresa Klinowska¹³, Brijesh Maroj¹³, Ganesh Moorthy¹⁴, Peter G. Mortimer¹³, Michele Moschetta¹³, Myria Nikolaou¹³, Liz Sainsbury¹³, Geoffrey I. Shapiro¹, Lillian L. Siu^{15,16}, and Aaron R. Hansen^{15,16}

ABSTRACT

Purpose: To characterize safety and tolerability of the selective PI3K β inhibitor AZD8186, identify a recommended phase II dose (RP2D), and assess preliminary efficacy in combination with abiraterone acetate or vistusertib.

Experimental Design: This phase I open-label study included patients with advanced solid tumors, particularly prostate cancer, triple-negative breast cancer, and squamous non-small cell lung cancer. The study comprised four arms: (i) AZD8186 monotherapy dose finding; (ii) monotherapy dose expansion; (iii) AZD8186/abiraterone acetate (with prednisone); and (iv) AZD8186/vistusertib. The primary endpoints were safety, tolerability, and identification of the RP2D of AZD8186 monotherapy and in combination. Secondary endpoints included pharmacokinetics (PK), pharmacodynamics, and tumor and prostate-specific antigen (PSA) responses.

Results: In total, 161 patients were enrolled. AZD8186 was well tolerated across all study arms, the most common adverse events

being gastrointestinal symptoms. In the monotherapy dose-finding arm, four patients experienced dose-limiting toxicities (mainly rash). AZD8186 doses of 60-mg twice daily [BID; 5 days on, 2 days off (5:2)] and 120-mg BID (continuous and 5:2 dosing) were taken into subsequent arms. The PKs of AZD8186 were dose proportional, without interactions with abiraterone acetate or vistusertib, and target inhibition was observed in plasma and tumor tissue. Monotherapy and combination therapy showed preliminary evidence of limited antitumor activity by imaging and, in prostate cancer, PSA reduction.

Conclusions: AZD8186 monotherapy had an acceptable safety and tolerability profile, and combination with abiraterone acetate/prednisone or vistusertib was also tolerated. There was preliminary evidence of antitumor activity, meriting further exploration of AZD8186 in subsequent studies in PI3K β pathway-dependent cancers.

Introduction

The PI3K signaling pathway plays an important role in many tumor types, controlling cell growth, proliferation, survival, metabolism, migration, and angiogenesis (1–3). PI3K enzyme complexes comprise a heterodimer between a p110 catalytic subunit and a p85 regulatory subunit. The p110 catalytic subunit is further subdivided into four isoforms: PI3K α , PI3K β , PI3K δ , and PI3K γ (4). Although the PI3K γ and δ isoforms are largely associated with regulation of immune

cells (5, 6), PI3K β has a broader tissue distribution and plays a key role in driving tumor progression, particularly in scenarios of inactivation or loss of the tumor-suppressor gene PTEN (7, 8). Increased PI3K signaling driven by PTEN loss is implicated in the development of solid tumors, including breast, colon, lung, and prostate (9).

Development of PI3K inhibitors is challenging because of toxicity risks associated with inhibiting multiple isoforms, so one way to optimize efficacy while minimizing potential toxicity is to develop isoform-specific drugs. AZD8186 is a potent, selective inhibitor of

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. ²Department of Medical Oncology, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, Washington. ³Drug Development Unit, The Institute of Cancer Research and Royal Marsden, London, United Kingdom. ⁴The Christie NHS Foundation Trust and The University of Manchester, Manchester, United Kingdom. ⁵Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, New York. ⁶Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin. ⁷Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain. ⁸University College London (UCL) Cancer Institute and UCL Hospital, London, United Kingdom. ⁹Department of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan. ¹⁰Cancer Research UK Cambridge Center, Cambridge, United Kingdom. ¹¹Department of Medical Oncology (Hospital Clinic Barcelona)/Translational Genomics and Targeted Therapies in Solid Tumors (IDIBAPS), Barcelona, Spain. ¹²Hospital Universitario, Quiron Madrid, Madrid, Spain. ¹³Oncology R&D, AstraZeneca, Cambridge, United Kingdom. ¹⁴Clinical Pharmacology & Quantitative

Pharmacology (CPQP), Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Boston, Massachusetts. ¹⁵Division of Medical Oncology and Hematology, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Ontario, Canada. ¹⁶Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Note: Supplementary data for this article are available at Clinical Cancer Research Online (<http://clincancerres.aacrjournals.org/>).

Corresponding Author: Aaron R. Hansen, Princess Margaret Cancer Center, 700 University Avenue, Suite 7-623, Toronto, ON M5G 1×6, Canada. E-mail: aaron.hansen@uhn.ca

Clin Cancer Res 2022;XX:XX-XX

doi: 10.1158/1078-0432.CCR-21-3087

This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 International (CC BY-NC-ND).

©2022 The Authors; Published by the American Association for Cancer Research

Translational Relevance

The PI3K signaling pathway plays an important role in many tumor types, but development of PI3K inhibitors is challenging because of toxicity risks associated with inhibiting multiple PI3K isoforms. AZD8186 is a potent, selective inhibitor of PI3K β . In this phase I open-label study, we evaluated the safety, tolerability, and recommended phase II dose of AZD8186 monotherapy and in combination with abiraterone acetate or vistusertib. Eligible patients had advanced prostate cancer, triple-negative breast cancer, or squamous non-small cell lung cancer, and patients with other solid tumor types were eligible if they were PTEN deficient/mutated or PIK3CB mutated/amplified. As monotherapy and in combination, AZD8186 was well tolerated, with few dose-limiting toxicities reported. Both monotherapy and combination therapy showed preliminary evidence of antitumor activity, which merits further assessment in subsequent studies.

PI3K β (IC₅₀, 4 nmol/L), with minimal activity against PI3K δ and selectivity over PI3K α and γ (10, 11). Preclinically, AZD8186 has single-agent activity across cell lines and tumor models enriched for PTEN loss. In PTEN-null tumor models, AZD8186 combines in an additive manner with antiandrogens (e.g., abiraterone acetate), docetaxel, PI3K pathway inhibitors (e.g., PI3K α inhibitors AZD8835 and BYL719), and the mTORC 1/2 inhibitor vistusertib, to deliver increased antitumor activity (10, 12, 13). The vistusertib combination was initiated to determine its potential to achieve comprehensive targeting of PI3K pathway. This was in response to a number of preclinical studies that demonstrated PI3K pathway reactivation attributed to vistusertib's intrinsic mechanisms of resistance (12, 14).

We present data from a first-in-human, phase I, open-label, multicenter study of AZD8186 in patients with solid tumors. The aims were to: characterize safety and tolerability; identify a recommended phase II dose (RP2D) for different schedules of AZD8186 monotherapy and in combination with abiraterone acetate (with prednisone) or vistusertib; and assess the preliminary efficacy of AZD8186 combined with abiraterone acetate or vistusertib in PTEN-mutated/deficient or PIK3CB-mutated/amplified triple-negative breast cancer (TNBC) or metastatic castration-resistant prostate cancer (mCRPC), respectively.

Materials and Methods

Study design

This phase I, open-label, multicenter trial (ClinicalTrials.gov: NCT01884285) was conducted at 13 centers in Canada, the United States, Spain, and the UK between July 2013 and February 2020. The study had a multi-arm design (Supplementary Fig. S1) and included patients with mCRPC, TNBC, and squamous non-small cell lung cancer (sqNSCLC). Patients with other advanced solid tumors with known PTEN deficiency/mutation or mutation/amplification of PIK3CB were included if the tumors were resistant to standard therapies, or no standard therapies were available.

The study comprised four arms (Supplementary Fig. S1). In an AZD8186 monotherapy dose-finding arm, patients received escalating doses and different schedules of AZD8186 monotherapy [5 days on, 2 days off (5:2); 2 days on, 5 days off (2:5); or continuous daily dosing]. Intermittent dosing schedules were investigated initially in preclinical studies and the 5:2 schedule was found to be as efficacious as

continuous dosing. Hence, the intermittent schedules were taken forward into the combination arms.

All AZD8186 doses were given twice daily (BID) on an empty stomach (at least 2 hours before and 1 hour after dosing) with two doses taken at least 12 hours apart. From a starting dose of 30-mg BID (based on non-clinical efficacy and toxicity studies), escalations to higher dose levels (60, 120, 180, 240, and 360-mg BID) were permitted if no dose-limiting toxicity (DLT) was observed in a cohort of three to six evaluable patients after review of safety data from three or more evaluable patients. The cohort was expanded to include six evaluable patients if one patient experienced a DLT, but recruitment ceased if two or more patients experienced a DLT.

In an AZD8186 monotherapy dose-expansion arm, patients with PTEN-deficient/mutated mCRPC or TNBC willing to undergo paired tumor biopsies (pre-dose and on-treatment) received AZD8186 at dose(s) and schedule(s) defined from the dose-finding arm.

In an AZD8186/abiraterone acetate dose-finding arm, patients with mCRPC received AZD8186 (60 or 120-mg BID; 5:2 schedule), plus abiraterone acetate 1,000 mg and prednisone 10 mg once daily in a fasted state (water only for at least 2 hours prior and 1 hour after each dose). In a dose-expansion cohort, patients with PTEN-deficient/mutated or PIK3CB-mutated/amplified mCRPC received AZD8186 plus abiraterone acetate and prednisone at the doses and schedule established in the dose-finding arm.

In an AZD8186/vistusertib dose-finding arm, patients with mCRPC, TNBC, sqNSCLC, or other solid tumors received AZD8186 [30, 60, or 120-mg BID (5:2)] plus vistusertib 100 mg or 125-mg BID (2:5). A dose-expansion cohort (AZD8186 plus vistusertib in patients with PTEN-deficient/mutated or PIK3CB-mutated/amplified TNBC) was planned but not conducted as clinical development of vistusertib was stopped.

PTEN deficiency (centrally determined by IHC using the CST138G6 PTEN antibody assay and defined by an H-score \leq 10; ref. 15) and deleterious alterations in PTEN and/or activating alterations in PIK3CB [determined by local testing using Clinical Laboratory Improvement Amendments (CLIA)-certified next-generation sequencing (NGS)] were prospectively examined in the dose-expansion cohorts. In the other study arms, testing was not mandatory, but PTEN IHC assessments were performed retrospectively when tissue was available.

The study was designed, conducted, and reported in accordance with the ethical principles of the Declaration of Helsinki (16). The protocol was approved by independent ethics committees and institutional review boards at each study site. All patients provided written informed consent.

Study population

Eligible patients were adults (\geq 18 years old) with an Eastern Cooperative Oncology Group performance status of 0 or 1. All patients had histologically or cytologically proven advanced cancer: mCRPC, sqNSCLC, TNBC, or confirmed PTEN-deficient/mutated or PIK3CB-mutated/amplified solid malignancy that had progressed after standard-of-care treatment. Patients with mCRPC were required to have a baseline prostate-specific antigen (PSA) level \geq 2 ng/mL. In the AZD8186/abiraterone acetate arms, patients could have received treatment with abiraterone acetate, enzalutamide, and/or docetaxel. The key exclusion criteria included: prior exposure to AZD8186 or any inhibitor of PI3K, AKT or mTOR; any cytotoxic chemotherapy, investigational agents, or other anticancer drugs within 14 days before study enrollment; and inadequate bone marrow reserve or organ function. Full inclusion/exclusion criteria are provided in Supplementary Table S1.

Endpoints

The primary endpoints of the study were safety and tolerability, and identification of the RP2D of AZD8186 monotherapy and in combination with abiraterone/prednisone or vistusertib. Secondary endpoints included the pharmacokinetic (PK) and pharmacodynamic (PD) properties of AZD8186, tumor response, and, in patients with mCRPC, PSA response.

Assessments

Safety and tolerability

All adverse events (AE) and serious AEs (SAE), including DLTs, were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4) and classified according to the Medical Dictionary for Regulatory Activities (version 20.0). A DLT was defined as any hematological or non-hematological severe treatment-related toxicity (i.e., not attributable to the disease or disease-related processes under investigation) during the first 21 days of multiple dosing (see the Supplementary Appendix for further details).

PK

PK sampling was performed to evaluate single-dose and steady-state PK of AZD8186 and its active metabolite (AZ13472080; M1) during monotherapy and combination therapy. Details of schedules for collection of blood samples for PK analyses are described in Supplementary Table S2. The concentrations of AZD8186 in plasma were determined using a validated bioanalytical method (see the Supplementary Appendix for details). PK analyses were performed by non-compartmental analyses using Phoenix WinNonlin software (version 6.3).

Tumor response

Tumor assessments were performed according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1; ref. 17) at baseline and every 6 weeks (every 12 weeks for mCRPC) until treatment discontinuation or withdrawal of consent. For patients with measurable disease, tumor response was defined as complete response, partial response, stable disease, or progressive disease.

PWGC2 response

For patients with mCRPC, bone lesions were assessed according to the Prostate Cancer Clinical Trials Working Group (PCWG2) guidelines at baseline and every 12 weeks until treatment discontinuation or withdrawal of consent (18, 19). PCWG2 progression was defined as two or more new metastatic bone lesions confirmed on bone scan, compared with the prior scan.

PSA response

For patients with mCRPC, PSA assessments were performed at baseline and at least once every cycle. PSA response was defined as decline of >50% versus baseline, confirmed at the next measurement at least 4 weeks later (20). PSA progression was defined as an increase of $\geq 25\%$ and ≥ 2 ng/mL above the nadir, confirmed by a second value ≥ 3 weeks later (19).

PD

Blood samples were collected at scheduled timepoints during AZD8186 monotherapy. As PI3K β controls pathway activation and regulates platelet function, changes in biomarkers of PI3K β inhibition were assessed in platelet-rich plasma. The ratios of phosphorylated (p) AKT1, including pAKT (T308) and pAKT (S473):total AKT, and

pGSK3 β :total GSK β were assessed using solid-phase enzyme-linked immunosorbent Mesoscale Discovery multiplex assays.

Paired fresh tumor biopsies were collected during the AZD8186 monotherapy arms at screening and after ≥ 3 consecutive days of dosing during Week 2 (preferably 2–4 hours post-AZD8186 dosing). pAKT (S473) and PRAS40 were assessed by IHC in three non-consecutive sections as previously described (21). Digital image analysis by HALO (Indica Laboratories) was used to quantify pAKT (S473) staining intensity specifically at the cellular membrane as a measure of active AKT (22, 23). pPRAS40 staining intensity was assessed in the cytosolic location.

Statistical analyses

The number of patients enrolled was that required to obtain adequate tolerability, safety, and PK data while exposing as few patients as possible to the investigational product and procedures. In the dose-finding arms, three to six evaluable patients were allocated for each cohort. In the dose-expansion arms, ≥ 12 evaluable patients were required. Definitions of the analysis sets used in this study, including the safety, PK, PD, and efficacy sets, are presented in the Supplementary Appendix.

Statistical evaluation was performed using SAS software (version 9.4). Descriptive statistics were used to measure safety, PK, and antitumor response. Waterfall plots, indicating the percentage of change from baseline, were generated for RECIST and PSA response.

In the combination therapy arms, PK interaction was evaluated by comparing the C_{\max} value and area under the concentration–time curve (AUC) of AZD8186 observed in the monotherapy dose-finding arm to those observed with combination therapy. A mixed effects model with treatment as a fixed effect and patient as a random effect was used to compare log-transformed AUC_{0-t} and C_{\max} values of these treatments. Geometric least squares means and confidence limits were calculated by exponentiation and the drug effect was exponentially back-transformed onto the original scale. For the AZD8186/abiraterone acetate combination, a pooled analysis of 120-mg dose groups from the dose-finding and dose-escalation cohorts was also conducted.

Data availability

Data underlying the findings described previously in this article may be obtained in accordance with AstraZeneca's data sharing policy described at <https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure>.

Results

Baseline characteristics and study attrition

In total, 161 patients were enrolled, including 67, 25, 35, and 34 in the monotherapy dose-finding, monotherapy dose-expansion, AZD8186/abiraterone acetate, and AZD8186/vistusertib arms, respectively. Of these, 147 patients [$n = 63$ (94.0%), 20 (80.0%), 34 (97.1%), and 30 (88.2%), respectively] received at least one dose of study medication (Supplementary Fig. S2). Of 14 patients who were enrolled but did not receive study treatment, the most common reason was failure to fulfill eligibility criteria ($n = 10$). The most common reason for AZD8186 discontinuation in each study arm was disease progression [monotherapy dose-finding arm, 71.4% ($n = 45$); monotherapy dose-expansion arm, 90.0% ($n = 18$); AZD8186/abiraterone acetate arm, 64.7% ($n = 22$); AZD8186/vistusertib arm, 53.3% ($n = 16$); Supplementary Fig. S2]. Across the four study arms, median age was 60–70 years (Table 1). Most patients were male (60%–100%) and had

Table 1. Baseline characteristics (safety analysis set).

	AZD8186 monotherapy (dose finding) <i>n</i> = 63 ^a	AZD8186 monotherapy (dose expansion) <i>n</i> = 20 ^a	AZD8186 + AAP <i>n</i> = 34 ^a	AZD8186 + vistusertib <i>n</i> = 30 ^a
Median age, years (range)	64.0 (18–92)	60.0 (41–76)	70.0 (42–83)	65.0 (45–89)
Sex, <i>n</i> (%)				
Male	49 (77.8)	12 (60.0)	34 (100)	25 (83.3)
Female	14 (22.2)	8 (40.0)	0	5 (16.7)
ECOG performance status, <i>n</i> (%)				
0	19 (30.2)	4 (20.0)	27 (79.4)	10 (33.3)
1	44 (69.8)	16 (80.0)	7 (20.6)	20 (66.7)
PTEN IHC status				
Deficient	20 (31.7)	17 (85.0)	22 (64.7)	6 (20.0)
Proficient	7 (11.1)	1 (5.0)	4 (11.8)	10 (33.3)
Unknown/not determined	36 (57.1)	2 (10.0)	8 (23.5)	14 (46.7)
Primary tumor location, <i>n</i> (%)				
Prostate	41 (65.1)	13 (65.0)	34 (100)	20 (66.7)
Breast	10 (15.9)	2 (10.0)	0	2 (6.7)
Lung	6 (9.5)	0	0	2 (6.7)
Other ^b	6 (9.5)	5 (25.0)	0	5 (16.7)
Unknown	0	0	0	1 (3.3)
Extent of disease, <i>n</i> (%)				
Metastatic	53 (84.1)	20 (100)	34 (100)	29 (96.7)
Locally advanced	10 (15.9)	0	0	1 (3.3)
Recurrence of earlier cancer, <i>n</i> (%)				
No	40 (63.5)	16 (80.0)	21 (61.8)	26 (86.7)
Yes	23 (36.5)	4 (20.0)	13 (38.2)	4 (13.3)
Prior anticancer therapy received				
1 line	7 (11.1)	3 (15.0)	8 (23.5)	3 (10.0)
2 lines	2 (3.2)	3 (15.0)	9 (26.5)	4 (13.3)
3 lines	13 (20.6)	6 (30.0)	8 (23.5)	5 (16.7)
4 lines	7 (11.1)	1 (5.0)	5 (14.7)	4 (13.3)
5+ lines	33 (52.4)	7 (35.0)	4 (11.8)	14 (46.7)
Unspecified	1 (1.6)	0	0	0
Median time from diagnosis to first dose, days (range)	1,890 (406–9,050)	1,384 (346–7,311)	1,992 (142–7,416)	2,553 (459–7,516)

Abbreviations: AAP, abiraterone acetate and prednisone; ECOG, Eastern Cooperative Oncology Group; IHC, immunohistochemistry; PTEN, phosphatase and tensin homolog.

^aAll patients received at least one dose of AZD8186.

^bIncluding biliary tract, colon, colorectal, head and neck, rectal, skin/soft tissue, and uterus.

metastatic disease (84%–100%), and the most common primary tumor location was prostate (65%–100%). The distribution of patients across the different doses and schedules is shown in **Table 2**.

AZD8186 monotherapy

Monotherapy dose-finding arm

The median (range) total treatment duration for AZD8186 in the monotherapy dose-finding arm was 47 (5–597) days (**Table 2**).

DLTs and definition of RP2D: Of 63 patients in the safety analysis set, 53 were evaluable for DLTs. Four patients (7.5%) experienced a DLT [one patient in each of the 120-mg BID (5:2) and 300-mg BID (5:2) cohorts and two patients in the 360-mg BID (5:2) cohort]. In all four patients, the DLT was a grade 3 rash (macular, maculo-papular, or unspecified). One patient in the 360-mg BID (5:2) cohort, in addition to grade 3 macular rash, experienced grade 2 abdominal pain and nausea, and grade 1 diarrhea and vomiting, which were considered as AEs of special interest and counted as DLTs.

The RP2D of AZD8186 monotherapy was formally declared as 60-mg BID (5:2) by the safety review committee at the end of dose-escalation period and was, therefore, further investigated in the expansion arm. However, on the basis of subsequent evaluation of

the overall safety profile observed at the different monotherapy schedules and doses evaluated in the monotherapy dose escalation, doses of 120-mg BID (continuous and 5:2) were later considered to be tolerated and further evaluated in subsequent arms of the study.

Safety and tolerability: All 63 patients experienced at least one AE, with 55 patients (87.3%) experiencing an AE considered causally related to AZD8186 (**Table 3**). Grade ≥ 3 events causally related to AZD8186 were reported in 20 patients (31.7%) and SAEs causally related to AZD8186 were reported in 10 patients (15.9%; Supplementary Table S4). The most common causally related AEs were diarrhea (41.3%; *n* = 26), nausea (27.0%; *n* = 17), vomiting (23.8%; *n* = 15), and fatigue (22.2%; *n* = 14; **Fig. 1A**). The most common grade ≥ 3 causally related AEs were anemia, aspartate aminotransferase increase, colitis, hypophosphatemia, and maculo-papular rash (all 4.8%; *n* = 3), which were reversible with dose interruption and/or supportive care. Single cases of grade 4 AEs were observed, of which one event each of hypokalemia (120-mg BID; 5:2) and platelet count decreased (180-mg BID; 5:2) were considered related to AZD8186 treatment. Eleven patients (17.5%) had AEs leading to discontinuation of study treatment (Supplementary Table S5). No deaths were reported in the AZD8186 monotherapy dose-finding arm.

Table 2. Summary of AZD8186 exposure (safety analysis set).

Study arm	AZD8186 dosing regimen	N	Relative dose intensity (mean %; SD)	Treatment cycles received (median; IQR)	Total treatment duration (days; median; range)
AZD8186 monotherapy dose finding	30 mg BID (5:2)	7	96.5 (6.1)	1.0 (1.0–2.0)	26.0 (8–82)
	60 mg BID (5:2)	6	98.5 (2.6)	3.0 (2.0–4.0)	75.0 (26–113)
	120 mg BID (5:2)	13	89.1 (18.7)	2.0 (1.0–3.0)	40.0 (12–194)
	240 mg BID (5:2)	6	99.2 (1.4)	1.5 (1.0–2.0)	26.0 (5–166)
	360 mg BID (5:2)	6	84.7 (25.9)	2.0 (1.0–2.0)	40.0 (10–83)
	300 mg BID (5:2)	2	37.8 (2.2)	1.0 (1.0–1.0)	20.5 (19–22)
	180 mg BID (5:2)	4	75.2 (15.9)	2.0 (1.5–2.5)	41.5 (19–69)
	30 mg BID (continuous)	4	89.1 (10.9)	5.0 (4.5–6.0)	136.5 (105–184)
	60 mg BID (continuous)	3	96.2 (6.1)	2.0 (2.0–3.0)	37.0 (33–85)
	120 mg BID (continuous)	5	83.1 (18.5)	2.0 (2.0–3.0)	61.0 (56–70)
	240 mg BID (2:5)	3	86.6 (7.6)	4.0 (2.0–21.0)	104.0 (36–597)
AZD8186 monotherapy dose expansion	60 mg BID (5:2)	12	97.8 (3.8)	2.0 (1.0–3.5)	42.0 (8–145)
	120 mg BID (continuous)	8	96.6 (9.1)	3.0 (2.0–9.0)	72.0 (28–364)
AZD8186 + AAP	Dose finding: 60 mg BID (5:2)	5	96.9 (5.1)	7.0 (4.0–9.0)	186.0 (82–278)
	Dose expansion: 120 mg BID (5:2)	11	86.7 (22.7)	3.0 (2.0–6.0)	79.0 (15–534)
	Dose expansion: 120 mg BID (5:2)	18	86.8 (17.7)	4.5 (3.0–8.0)	112.0 (5–337)
AZD8186 + vistusertib	30 mg BID (5:2) + 100 mg vistusertib	7	90.5 (8.5)	2.0 (1.0–3.0)	40.0 (7–390)
	60 mg BID (5:2) + 100 mg vistusertib	4	78.4 (17.5)	3.0 (2.5–3.5)	78.5 (41–105)
	60 mg BID (5:2) + 125 mg vistusertib	4	79.8 (14.2)	2.0 (1.0–3.5)	59.0 (3–110)
	120 mg BID (5:2) + 125 mg vistusertib	10	77.9 (38.8)	2.5 (1.0–4.0)	71.5 (12–208)
	120 mg BID (5:2) + 100 mg vistusertib	5	96.6 (4.5)	2.0 (1.0–2.0)	35.0 (16–44)

Note: Dosing of AZD8186 was 5 days on, 2 days off (5:2); 2 days on, 5 days off (2:5), or continuous.

Abbreviations: AAP, abiraterone acetate plus prednisone; BID, twice daily; IQR, interquartile range; SD, standard deviation.

^aOverall treatment duration.

Dose interruption or reduction was reported in 31 (49.2%) and 11 (17.5%) patients, respectively (Supplementary Table S3). At least one dose interruption was reported in each dose cohort, and most interruptions were related to AEs ($n = 24$; 38.1%). Of the 11 patients with dose reductions, 10 had reductions related to AEs; in the remaining patient the reduction was due to “other” (unspecified) reasons (Supplementary Table S3).

PK: AZD8186 was absorbed rapidly in plasma with a median T_{max} value of 1.2–4.1 hours for a single dose, and 1.5–3.0 hours for multiple dosing (Supplementary Fig. S3). A similar profile was seen for the equipotent metabolite M1, with median T_{max} value of 2.0–6.0 hours and 2.2–6.0 hours for single and multiple AZD8186 dosing, respectively (Supplementary Fig. S4). A summary of PK parameters for AZD8186 and M1 is presented in Supplementary Tables S6 and S7, respectively. After single- and multiple-dose administration, C_{max} and AUC values increased with dose for both AZD8186 and M1. Geometric mean terminal elimination half-life for AZD8186 after a single dose ranged from 2.1 to 6.2 hours, with an overall range of 1.4–13.8 hours, and for M1 ranged from 4.2 to 8.6 hours, with a range of 3.2–13.0 hours.

Efficacy: In total, 34 patients were evaluable by RECIST 1.1. Of 18 patients with non-prostate cancer, a confirmed partial response (duration, 372 days) was reported in one patient (5.6%; 120-mg BID; 2:5), who had PTEN-deficient colorectal carcinoma. The tumor was classified as microsatellite instability-high by local testing, and central NGS analyses revealed many clinically relevant mutations, including *KRAS* G13D and deleterious mutations in *PTEN*, *PIK3R2*, and *SETD2*. The remaining patients had a best objective response of stable disease ($n = 7$; 38.9%) or disease progression ($n = 10$; 55.6%). Of 16 patients

with prostate cancer, 6 (37.5%) had a best objective response of stable disease and 10 (62.5%) had disease progression.

Of 40 patients with prostate cancer that were PSA evaluable at baseline, one patient (2.5%; 240-mg BID; 2:5) experienced a partial PSA response (PTEN status unknown) and one patient (2.5%) experienced PSA progression. Of the remaining 38 patients, 34 (85.0%) did not meet the criteria for response or progression, and 4 (10.0%) were not evaluable at follow-up.

Monotherapy dose-expansion cohort

Patients in the monotherapy dose-expansion arm received either AZD8186 60-mg BID (5:2) or 120-mg BID (continuous; **Table 2**). Median (range) total treatment duration for AZD8186 was 59.0 (8–364) days (**Table 2**).

Safety and tolerability: Both AZD8186 doses were well tolerated. Of 20 patients in the safety analysis set, 19 (95.0%) experienced at least one AE. Eleven patients (55.0%) experienced an AE considered to be causally related to AZD8186 (**Table 3**). Grade ≥ 3 events causally related to AZD8186 were reported in three patients (15.0%) and SAEs causally related to AZD8186 were reported in two patients (10.0%; Supplementary Table S4). As in the monotherapy dose-finding arm, the most common treatment-related AEs were gastrointestinal symptoms (**Fig. 1B**). One patient had an AE leading to discontinuation of study treatment (Supplementary Table S5). No grade ≥ 3 treatment-related AEs were reported in more than one patient and no grade 4 AEs or deaths were reported.

Dose interruption was reported in seven patients (35.0%), six of whom were in the 60-mg BID (5:2) cohort (Supplementary Table S3). The most common reasons for dose interruption were forgetting to take the dose ($n = 3$) and AEs ($n = 2$). No dose reductions were reported.

Table 3. AEs reported with AZD8186 therapy (safety analysis set).

Event, n (%)	AZD8186 monotherapy (dose finding) n = 63	AZD8186 monotherapy (dose expansion) n = 20	AZD8186 + AAP (dose finding) n = 16	AZD8186 + AAP (dose expansion) n = 18	AZD8186 + vistusertib n = 30
Any AE	63 (100.0)	19 (95.0)	16 (100)	18 (100)	29 (96.7)
Any AE causally related to AZD8186 only	55 (87.3)	11 (55.0)	12 (75.0)	15 (83.3)	27 (90.0)
Any AE causally related to abiraterone acetate only	—	—	10 (62.5)	15 (83.3)	—
Any AE causally related to vistusertib only	—	—	—	—	26 (86.7)
Any grade ≥3 AE	39 (61.9)	8 (40.0)	9 (56.3)	14 (77.8)	23 (76.7)
Any grade ≥3 AE causally related to AZD8186 only	20 (31.7)	3 (15.0)	5 (31.3)	8 (44.4)	17 (56.7)
Any grade ≥3 AE causally related to abiraterone acetate only	—	—	4 (25.0)	7 (38.9)	—
Any grade ≥3 AE causally related to vistusertib only	—	—	—	—	17 (56.7)
Death	0	0	1 (6.3)	1 (5.6)	2 (6.7)
Death causally related to AZD8186 only	0	0	0	0	0
Death causally related to abiraterone acetate only	—	—	0	0	—
Death causally related to vistusertib only	—	—	—	—	0
Any SAE (including deaths)	23 (36.5)	4 (20.0)	9 (56.3)	10 (55.6)	15 (50.0)
Any SAE (including deaths), causally related to AZD8186 only	10 (15.9)	2 (10.0)	3 (18.8)	3 (16.7)	11 (36.7)
Any SAE (including deaths), causally related to abiraterone acetate only	—	—	0	3 (16.7)	—
Any SAE (including deaths), causally related to vistusertib only	—	—	—	—	11 (36.7)
Any SAE causing discontinuation of AZD8186	6 (9.5)	0	3 (18.8)	2 (11.1)	3 (10.0)
Any SAE causing discontinuation of AZD8186, causally related to AZD8186 only	5 (7.9)	0	2 (12.5)	0	1 (3.3)
Any SAE causing discontinuation of AZD8186, causally related to abiraterone acetate only	—	—	0	1 (5.6)	—
Any SAE causing discontinuation of AZD8186, causally related to vistusertib only	—	—	—	—	1 (3.3)
Any AE leading to discontinuation of AZD8186	11 (17.5)	1 (5.0)	5 (31.3)	4 (22.2)	6 (20.0)
Any AE leading to discontinuation of abiraterone acetate	—	—	3 (18.8)	5 (27.8)	—
Any AE leading to discontinuation of vistusertib	—	—	—	—	6 (20.0)
Any AE leading to dose modification of AZD8186	10 (15.9)	0	2 (12.5)	3 (16.7)	5 (16.7)
Any AE leading to dose modification of abiraterone acetate	—	—	2 (12.5)	7 (38.9)	—
Any AE leading to dose modification of vistusertib	—	—	—	—	4 (13.3)
Dose-limiting toxicities	4 (7.7) ^a	—	0 ^b	—	1 (5.0) ^c

Abbreviations: AAP, abiraterone acetate plus prednisone; AE, adverse event; SAE, serious adverse event.

^an = 53 evaluable patients.

^b14 evaluable patients.

^cn = 20 evaluable patients

Efficacy: Of seven patients with non-prostate cancer with RECIST 1.1 measurable disease, 1 (14.3%) had a best objective response of stable disease and 6 (85.7%) had disease progression. Of eight patients with prostate cancer with RECIST 1.1 measurable disease, 6 (75.0%) had a best objective response of stable disease and 2 (25.0%) had disease progression.

Of 13 patients with prostate cancer that were PSA evaluable at baseline, one patient (7.7%; 120-mg BID) had a partial PSA response (PTEN deficiency confirmed) and 1 (7.7%) had PSA progression. Of the remaining 11 patients, 9 (69.2%) did not meet the criteria for response or progression, and two patients (15.4%) were not evaluable at follow-up.

PD (monotherapy dose-finding and dose-expansion arms)

Substantial reductions were seen in the platelet-rich plasma analyses of proximal markers of PI3K β inhibition [pAKT (S473), pAKT (T308), and pGSK3 β], with slightly deeper and longer reduction in the pooled 120-mg BID monotherapy cohort compared with the pooled 60-mg BID cohort (Fig. 2A–C). Data for all doses and cohorts in the monotherapy dose-finding arm for pAKT (S473):tAKT (S473) and pGSK3 β :tGSK3 β are shown in Supplementary Fig. S5. In an explor-

atory analysis investigating free plasma exposure of the active moiety (AZD8186 and M1), a good correlation with the peripheral PD markers pAKT (S473), pAKT (T308), and pGSK3 β was observed.

IHC staining of paired biopsies from six patients in the 120-mg BID cohort of the monotherapy dose-expansion arm showed a substantial reduction in the PI3K β downstream marker pAKT (S473) membrane fraction in all six patients and the AKT downstream marker pPRAS40 in five of the six patients (Fig. 2D and E; Supplementary Table S8). Representative IHC staining of tumor biopsies is shown in Fig. 2F and G).

AZD8186 + abiraterone acetate

Dose-finding arm

AZD8186 dosing in the AZD8186/abiraterone acetate dose-finding arm (n = 16) was based on safety and efficacy findings in the monotherapy dose-finding arm, with patients receiving 60 or 120-mg AZD8186 BID (5:2; Table 2). Median (range) treatment duration was 186.0 (82–278) days for AZD8186 60-mg BID (5:2) and 79.0 (15–534) days for AZD8186 120-mg BID (5:2). Median (range) duration of abiraterone acetate treatment was 186.0 (83–280) days and 67.0 (18–252) days, respectively.




Figure 1.

Summary of treatment-related AEs* by maximum reported CTCAE grade in the monotherapy (**A**) dose-finding and (**B**) dose-expansion arms (safety analysis set). *, AEs considered by the investigator to be related to AZD8186 treatment occurring in $\geq 10\%$ of patients in the dose-finding or dose-expansion arms, respectively. AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CTCAE, Common Terminology Criteria for Adverse Events; ECG QT, electrocardiogram QT interval

DLTs and definition of RP2D: In 14 patients evaluable for DLT, no DLTs were observed when AZD8186 was combined with abiraterone acetate. AZD8186 120-mg BID (5:2) was, therefore, considered to be the RP2D in combination with the clinically approved abiraterone/prednisone dose, and was further evaluated in the expansion cohort.

Safety and tolerability: AEs were reported in all 16 patients in the safety analysis population. Grade ≥ 3 AEs causally related to AZD8186

only or abiraterone acetate only were reported in five patients (31.3%) and four patients (25.0%), respectively (**Table 3**). SAEs causally related to AZD8186 only were reported in three patients (18.8%; Supplementary Table S4). No SAEs were considered causally related to abiraterone acetate only. One death (6.3%; respiratory failure) was reported in a patient receiving AZD8186 120-mg BID (5:2) in the context of SAEs of sepsis, double pneumonia, and alcohol withdrawal syndrome. Neither the death nor the associated SAEs were considered to be




Figure 2. Assessment of PD biomarkers after treatment with AZD8186 (PD analysis set; pooled data for 60-mg and 120-mg BID cohorts). Mean ratio of (A) pAKT (S473):tAKT(S473); (B) pAKT (T308):tAKT (T308); and (C) pGSK3β:tGSK3β over time in platelet-rich plasma (AZD8186 monotherapy arms). Total H-scores (top) and the percentage of change from baseline (bottom) are shown for (D) membranous pAKT (S473) and (E) pPRAS40 in individual patients*. Examples of membrane (F) pAKT scoring by DIA and (G) pPRAS40 scoring pre-treatment and 4 hours after dose at CIW2† (PD analysis set). CID1, cycle 1 day 1; CIW2, cycle 1 week 2; DIA, digital image analysis; p, phosphorylated; t, total. *, Data for individual patients shown as different colors; †, On-treatment tumor biopsies were collected in week 2, after dose on days 11 or 12 for 5 days on/2 days off schedule or after dose on days 11–14 for continuous schedule.

causally related to AZD8186 or abiraterone acetate. The most common AEs causally related to AZD8186 were diarrhea (37.5%; $n = 6$) and nausea (37.5%; $n = 6$); diarrhea was the only AZD8186-related grade ≥ 3 treatment-related AE reported in more than one patient (12.5%; $n = 2$). Grade 4 AEs were reported in one patient in each of the two dose groups but were not considered to be causally related to AZD8186. Five patients (31.3%), all receiving AZD8186 120-mg BID (5:2), discontinued AZD8186 because of an AE (Supplementary Table S5).

Dose interruption or reduction of AZD8186 was reported in 9 (56.3%) and 2 (12.5%) patients, respectively (Supplementary Table S3). AEs were the most common reason for both dose interruption ($n = 8$) and reduction ($n = 2$). Dose interruption or

reduction of abiraterone acetate was reported in 9 (56.3%) and 3 (18.8%) patients, respectively, with AEs again the most common reason for dose interruption ($n = 9$) and reduction ($n = 2$). Dose interruption or reduction of prednisone was reported in 9 (56.3%) and 3 patients (18.8%), respectively. Despite these dose interruptions and reductions, the median relative dose intensities for AZD8186, abiraterone acetate, and prednisone were all $>90\%$ (Supplementary Table S9).

PK: The drug–drug interaction analysis comparing C_{max} and AUC_{τ} values of AZD8186 monotherapy with abiraterone acetate + AZD8186 suggests that abiraterone acetate has little or no effect on the PK profile of AZD8186 (Supplementary Fig. S6;




Figure 3. Best response for (A) target lesions, based on RECIST ($n = 12$ with measurable disease), and (B) PSA concentration ($n = 30$ evaluable for response) by patient and dose in the efficacy-evaluable analysis set (AZD8186/abiraterone acetate combination arm). *, Response was not confirmed at follow-up scan.

Supplementary Table S10). Similarly, there was little effect of AZD8186 on the PK of abiraterone acetate (Supplementary Fig. S7; Supplementary Table S10).

Efficacy: Among patients with RECIST 1.1 measurable disease ($n = 4$), three had stable disease and one (120-mg BID; 5:2) had a partial response (duration, 172 days; Fig. 3). This patient was not PTEN-deficient (PTEN mutation status not evaluated). Of note, the patient

with the partial response had not previously received abiraterone acetate, enzalutamide, or docetaxel, making it difficult to determine the relative contributions of AZD8186/abiraterone to this response.

Of 15 patients that were PSA evaluable at baseline, one patient (6.7%) receiving AZD8186 120-mg BID (5:2) had a complete response (duration, 197 days) in addition to the RECIST 1.1 partial response noted above. Of the remaining 14 patients, 13 (86.7%) had stable disease and one was not evaluable (6.7%; Fig. 3). Among patients

evaluable for PCWG2 bone-lesion response ($n = 10$), 6 (60.0%) had non-progressive disease and 4 (40.0%) had progressive disease (Supplementary Table S11).

Dose-expansion cohort

In the expansion cohort, 18 patients with CRPC received AZD8186 120-mg BID (5:2) in combination with abiraterone, with a median (range) duration of 112.0 (5–337) days (Table 2). Median duration of abiraterone acetate treatment was 86.0 (5–337) days. Of the 18 patients, 14 (77.8%) had previously received abiraterone and/or enzalutamide.

Safety and tolerability: AEs were reported in all 18 patients, with AEs causally related to AZD8186 only or abiraterone acetate only each reported in 15 patients (83.3%; Table 3). SAEs causally related to AZD8186 only or abiraterone acetate only, were each reported in three patients (16.7%). One death (5.6%; metastatic prostate cancer) was reported during the safety follow-up period and was not considered to be causally related to study drug. The most common AEs causally related to AZD8186 treatment were diarrhea (50.0%; $n = 9$), nausea (44.4%; $n = 8$), and vomiting (38.9%; $n = 7$). The most common grade ≥ 3 AEs causally related to AZD8186 treatment were alanine aminotransferase increased (16.7%; $n = 3$) and aspartate aminotransferase increased (16.7%; $n = 3$). One patient reported a grade 4 AE considered to be related to study treatment (alanine aminotransferase increased). Four patients (22.2%) discontinued AZD8186 because of an AE (Supplementary Table S5).

Dose interruption or reduction of AZD8186 was reported in 13 patients (72.2%) and four patients (22.2%), respectively, with AEs the most common reason for both interruption ($n = 10$; 55.6%) and reduction ($n = 4$; 22.2%; Supplementary Table S3). Dose interruption of abiraterone acetate and prednisone was reported in 13 patients (72.2%) and 14 patients (77.8%), respectively, with dose reductions in six patients (33.3%) and four patients (22.2%), primarily for AEs (reductions and interruptions) or forgetting to take the dose (reductions only).

Efficacy: Five of eight patients (62.5%) with RECIST 1.1-measurable disease had a best objective response of stable disease and 3 (37.5%) had progressive disease (Fig. 3). Of 15 patients that were PSA evaluable at baseline, one had a complete response (6.7%). This PTEN-deficient patient had not previously received treatment with abiraterone acetate, enzalutamide, or docetaxel. In addition, two patients (13.3%) had partial responses, both of whom had previously received enzalutamide and docetaxel (one PTEN deficient and one with a PTEN mutation). Of the remaining patients, 9 (60.0%) had stable disease, 1 (6.7%) had progressive disease, and 2 (13.3%) were not evaluable (Fig. 3). Of 14 patients evaluable for PCWG2 bone-lesion response, 9 (64.3%) had non-progressive disease, 4 (28.6%) had progressive disease, and one patient (7.1%) was not evaluable at follow-up (Supplementary Table S11).

AZD8186 + vistusertib

Seven patients received AZD8186 30-mg BID (5:2) + vistusertib 100 mg, four patients each received AZD8186 60-mg BID (5:2) + vistusertib 100 mg and AZD8186 60-mg BID (5:2) + vistusertib 125 mg, 10 patients received AZD8186 120-mg BID (5:2) + vistusertib 125 mg, and five received AZD8186 120 mg BID (5:2) + vistusertib 100 mg (Table 2). The median (range) duration of treatment was 42.5 (3–390) days for AZD8186 and 41.0 (2–387) days for vistusertib.

DLTs and definition of RP2D

Of 20 evaluable patients, one [AZD8186 120-mg BID (5:2) + vistusertib 125 mg] experienced three concurrent grade 3 DLTs (mucosal inflammation, maculo-papular rash, and blood phosphorus decreased). An RP2D of AZD8186 in combination with vistusertib was not formally declared, as enrollment in the AZD8186/vistusertib dose-finding arm was halted due to discontinuation of vistusertib development. The dose-expansion arm was not initiated.

Safety and tolerability: AEs were experienced by 29 patients (96.7%) in the safety analysis set, with grade ≥ 3 AEs causally related to AZD8186 only or vistusertib only each reported in 17 patients (56.7%; Table 3). SAEs causally related to AZD8186 only (Supplementary Table S4) or vistusertib only were each reported in 11 patients (36.7%). The most common AEs causally related to AZD8186 were diarrhea (56.7%; $n = 17$), nausea (53.3%; $n = 16$), and fatigue (36.7%; $n = 11$). The most common grade ≥ 3 causally related AEs were increased alanine aminotransferase and diarrhea (16.7%; $n = 5$ and 13.3%; $n = 4$, respectively). Six patients (20.0%) had an AE leading to discontinuation of AZD8186 (Supplementary Table S5). Two AEs leading to death (6.7%) were reported during safety follow-up (subarachnoid hemorrhage, $n = 1$; pulmonary embolism, $n = 1$); neither was considered to be causally related to study medication.

Overall, 20 patients (66.7%) and five patients (16.7%) had dose interruptions or reductions, respectively (Supplementary Table S3). The most common reasons for interruptions and reductions of AZD8186 were AEs (56.7% and 16.7%, respectively). Dose interruption or reduction of vistusertib occurred in 18 patients (60.0%) and seven patients (23.3%), respectively. No significant effects on cholesterol or glucose levels and blood pressure were observed following treatment with AZD8186 + vistusertib.

PK: The estimate of geometric mean ratio percentage for AZD8186 AUC_{0-12} and C_{max} values was not affected by the presence of vistusertib (Supplementary Table S12). As no data on vistusertib monotherapy were collected during the study, effects of AZD8186 on the PK of vistusertib could not be determined.

Efficacy: Of eight patients with non-prostate cancer with RECIST 1.1-measurable disease, 3 (37.5%) had a best objective response of stable disease and 5 (62.5%) had disease progression. Of nine patients with prostate cancer with RECIST 1.1-measurable disease, 1 (11.1%) had a best objective response of partial response (PTEN deficiency and mutation status unknown), 2 (22.2%) had stable disease, and 6 (66.7%) had disease progression.

Discussion

This was the first-in-human study of AZD8186, in which the optimal dosing and schedule were identified and supported by safety and PK data. AZD8186 had an acceptable safety and tolerability profile, both as monotherapy and in combination with abiraterone acetate (and prednisone) or vistusertib, when compared against other PI3K inhibitors such as copanlisib and idelalisib (24, 25). Dose-dependent effects of target inhibition were observed in plasma (60-mg and 120-mg BID AZD8186) and tumor tissue (120-mg BID AZD8186). The PKs of AZD8186 were dose proportional, without interactions with abiraterone acetate or vistusertib. AZD8186 (as monotherapy and in combination) also showed preliminary evidence of anti-tumor activity by both radiography and PSA reduction.

Dose discontinuations and reductions were consistent with rates described for licensed PI3K inhibitors, idelalisib and copanlisib (26, 27). Dose interruptions were slightly higher in the AAP and vistusertib combinations, mainly to allow patients to recover and restart therapy to derive further benefit from study medication.

Gastrointestinal AEs (constipation, diarrhea, nausea, and vomiting) and fatigue were the most frequently reported treatment-related AEs during AZD8186 treatment, and most were grade 1 or 2 in severity. In general, treatment-emergent AEs, including colitis, diarrhea, and rash, were easily manageable by best supportive care and short treatment interruptions at recommended doses but were dose limiting at the highest doses tested. This safety profile could be the consequence of PI3K δ inhibition at highest doses tested but not at the recommended doses where PI3K β inhibition prevails.

There was no clear pattern regarding the efficacy of AZD8186 in patients with PTEN alterations: of two patients with RECIST 1.1 partial responses, one had PTEN-deficient disease and one did not (mutation status unknown). Of five patients with prostate cancer with PSA responses, three were in PTEN-deficient disease, one was in PTEN-mutant disease, and one had no PTEN deficiency (mutation status unknown). It should be noted, however, that patient numbers were small, most patients with mCRPC were heavily pre-treated, and PTEN testing was mandatory only in the dose-expansion cohorts and was performed by IHC without assessment of genetic loss. AZD8186 remains to be tested in a different patient population and/or with a different combination partner other than abiraterone or vistusertib. Analogous data have been reported in similar studies, in which PTEN/PI3K mutation status was again evaluated only in a subset of study participants (28). Further studies with AZD8186 or other PI3K inhibitors will be needed to establish the predictive potential of PTEN as a biomarker. In addition, PTEN deficiency/inactivation is only one of several mechanisms leading to activation of the PI3K/AKT pathway (29). Several potential mechanisms of resistance to PI3K inhibitor treatment have been identified, including signaling through the RAS-MEK-ERK pathway via HRAS, compensatory increases in HER2/3 expression activating ERK signaling, and activation of the NOTCH-MYC pathway (30, 31).

A second PI3K β inhibitor, GSK2636771, is currently in development for solid tumors. As with AZD8186, first-in-human results confirmed clinically relevant target inhibition with the RP2D (400 mg) and a manageable safety profile (32), further demonstrating the proof of mechanism of this PI3K β inhibitor. A preliminary association between *PIK3CB* genomic aberrations and clinical benefit was also reported (32). As in the present study, the most common treatment-related AEs were gastrointestinal symptoms (diarrhea, nausea, and vomiting) and fatigue. A dual PI3K β / δ inhibitor, KA2237, has been investigated in patients with lymphoma, with preliminary results from a first-in-human study showing a manageable toxicity profile and promising single-agent clinical activity in heavily pretreated relapsed/refractory B-cell lymphoma (33).

The multi-arm trial design, allowing several different regimens, schedules, and combinations to be evaluated, is an important strength of the present study. However, the small numbers of patients in each treatment cohort mean that conclusions, particularly related to efficacy, should be drawn with care. In the future, trials with larger cohorts will be needed to further explore the efficacy and tolerability of AZD8186. Additional trials will also be needed to help understand whether PTEN deficiency or mutation status is predictive of response with PI3K β inhibitors. One avenue for future development is the combination of PI3K inhibitors with immunotherapy, such as T-cell vaccines and checkpoint inhibitors (34). Other possible combinations

for PI3K β inhibitors include docetaxel and paclitaxel, as well as other novel therapies such as PI3K α inhibitors in patients with hormone receptor-positive breast cancer who progress after alpelisib treatment, where PTEN deficiency is a known resistance mechanism (35). The efficacy and safety of AZD8186 are currently being evaluated in studies in combination with docetaxel in solid tumors (phase I; ClinicalTrials.gov: NCT03218826), and with weekly paclitaxel in gastric cancer (phase I/II; NCT04001569).

Conclusion

In this phase I study, optimal dosing for AZD8186 was identified and supported by PK and PD data. AZD8186 monotherapy at the selected RP2D had an acceptable safety and tolerability profile, and combination with abiraterone acetate (and prednisone) or vistusertib was also tolerated. Target inhibition was observed in plasma and tumor tissue at the RP2D selected for further development, and there was some preliminary evidence of antitumor activity. This merits further exploration of the potential of AZD8186 to affect PI3K β -driven disease in larger clinical studies, in a more precisely defined population and in combination with other agents targeting this pathway.

Authors' Disclosures

A.D. Choudhury reports grants from AstraZeneca during the conduct of the study; A.D. Choudhury also reports grants from Bayer, as well as personal fees from Clovis, Dendreon, Bayer, AstraZeneca, Astellas, and Blue Earth outside the submitted work. C.S. Higano reports grants from AstraZeneca, personal fees from AstraZeneca, and other support from AstraZeneca during the conduct of the study. C.S. Higano also reports personal fees from Advanced Accelerator Applications, Blue Earth, Dendreon, Janssen, Merck, Tolmar, Vaccitech, Menarini, Astellas, Bayer, Ferring, Pfizer, and Clovis; grants from Aptevo, Astellas, Bayer, Emergent, F. Hoffmann-La Roche, Ferring, Genentech, Medivation, Pfizer, and Clovis; and other support from Exelixis, Candel, Advanced Accelerator, Astellas, Bayer, Blue Earth, Ferring, Janssen, Merck, Pfizer outside the submitted work. J.S. de Bono reports grants and personal fees from AstraZeneca during the conduct of the study; J.S. de Bono also reports grants and personal fees from Amgen, Astellas, Bayer, Bioxeel Therapeutics, Boehringer Ingelheim, Cellcentric, Daiichi, Eisai, Genentech/Roche, Genmab, GSK, Harpoon, ImCheck Therapeutics, Janssen, Merck Serono, Merck Sharp & Dohme, Menarini/Silicon Biosystems, Orion, Pfizer, Qiagen, Sanofi Aventis, Sierra Oncology, Taiho, Terumo, and Vertex Pharmaceuticals outside the submitted work. In addition, J.S. de Bono reports a patent for DNA repair defects PARP (ICR owned patent) and does not receive royalties issued, and a patent for Abiraterone acetate (ICR owned patent) but does not receive any royalties issued. N. Cook reports grants from Cancer Research UK, other support from AstraZeneca, and grants from NIHR during the conduct of the study. N. Cook also reports non-financial support and other support from Roche; other support from Tarveda, Taiho, Pfizer, Bayer, Orion, Avacta, Eisai, UCB, Merck, Boehringer, Stemline, Starpharma, and Ergomed; and personal fees and other support from RedX outside the submitted work. D.E. Rathkopf reports other support from AstraZeneca during the conduct of the study, as well as other support from Janssen, Celgene/BMS, Genentech/Roche, Phosphatidyl, Myovant, AstraZeneca, Bayer, and Taiho outside the submitted work. K.B. Wisinski reports other support from AstraZeneca during the conduct of the study. K.B. Wisinski also reports grants and personal fees from Pfizer; personal fees from Sanofi, AstraZeneca, and Eisai; personal fees and other support from Novartis; and other support from Context Therapeutics outside the submitted work. J. Martin-Liberal reports personal fees from Astellas and Highlight Therapeutics; grants and personal fees from Bristol Myers Squibb, MSD, Novartis, Pierre Fabre, Pfizer, Roche, and Sanofi; and grants from Ipsen outside the submitted work. E.I. Heath reports other support from Astellas Pharma, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Caris Life Sciences, Celgene, Celldex, Corcept Therapeutics, Curemeta, Dendreon, eFFECTOR Therapeutics, Esanik, Fortis Therapeutics, Genentech/Roche, GlaxoSmithKline, Ignyta, Inovio Pharmaceuticals, Medivation, Merck Sharp & Dohme, Merck, Millennium, Oncology BioPharma, Plexicon, Sanofi, Seattle Genetics, Synta, Tokai Pharmaceuticals, and

Zenith Epigenetics outside the submitted work. R.D. Baird reports grants and personal fees from AstraZeneca and Genentech/Roche, as well as personal fees from Novartis during the conduct of the study. R.D. Baird also reports grants and personal fees from Boehringer Ingelheim, as well as personal fees from Shionogi, Daiichi-Sankyo, and Molecular Partners outside the submitted work. M. Quintela-Fandino reports grants from AstraZeneca during the conduct of the study; M. Quintela-Fandino also reports grants from Bayer, Boehringer Ingelheim, and MEI Pharma, as well as personal fees from Bayer and Pfizer outside the submitted work. S.T. Barry reports employment and shareholder at AstraZeneca. E.C. de Bruin reports personal fees from AstraZeneca during the conduct of the study, as well as personal fees from AstraZeneca outside the submitted work. E.C. de Bruin also reports patents for AZD8186 held by AstraZeneca. S. Colebrook reports personal fees from AstraZeneca during the conduct of the study, as well as personal fees from AstraZeneca outside the submitted work. S. Colebrook also reports AstraZeneca has Intellectual Property and Patents around AZD8186. G. Hawkins reports personal fees from AstraZeneca during the conduct of the study, as well as personal fees from AstraZeneca outside the submitted work. T. Klinowska reports other support from AstraZeneca during the conduct of the study, as well as other support from AstraZeneca outside the submitted work. B. Maroj reports other support from AstraZeneca during the conduct of the study, as well as other support from AstraZeneca outside the submitted work. G. Moorthy reports other support from AstraZeneca during the conduct of the study, as well as other support from AstraZeneca outside the submitted work. P.G. Mortimer reports other support from AstraZeneca during the conduct of the study, as well as other support from AstraZeneca outside the submitted work. M. Moschetta reports other support from AstraZeneca during the conduct of the study. M. Nikolaou reports other support from AstraZeneca during the conduct of the study, as well as other support from AstraZeneca outside the submitted work; M. Nikolaou also reports employment and shareholder at AstraZeneca. L. Sainsbury reports other support from AstraZeneca during the conduct of the study, as well as other support from AstraZeneca outside the submitted work. G.I. Shapiro reports other support from AstraZeneca during the conduct of the study. G.I. Shapiro also reports grants from Eli Lilly, Merck & Co.; grants and personal fees from Merck KGaA/EMD-Serono, Sierra Oncology, and Pfizer; and personal fees from Bicycle Therapeutics, Fusion Pharmaceuticals, Cybrexa Therapeutics, Bayer, Boehringer Ingelheim, ImmunoMet, Asana, Artios, Atrin, Concarlo Holdings, Syros, Zentalis, CytomX Therapeutics, Blueprint Medicines, Kymera Therapeutics, Janssen, and Xinthera outside the submitted work. In addition, G.I. Shapiro also reports a patent for Dosage regimen for sapacitabine and seliciclib issued to Cyclacel Pharmaceuticals and Geoffrey Shapiro, as well as a patent for Compositions and methods for predicting response and resistance to CDK4/6 inhibition pending to Liam Cornell and Geoffrey Shapiro. L.L. Siu reports personal fees from AstraZeneca and grants from AstraZeneca during the conduct of the study. L.L. Siu also reports personal fees from Merck, Pfizer, Roche, Symphogen, GlaxoSmithKline, Voronoi, Arvinas, Tessa, Navire, Relay Therapeutics, Rubius, Janpix, Daiichi Sankyo, Coherus, Amgen, Agios, Treadwell Therapeutics, and Marengo, as well as grants from Novartis, Bristol Myers Squibb, Pfizer, Boehringer Ingelheim, GlaxoSmithKline, Roche/Genentech, Merck, AbbVie, Astellas, Bayer, Amgen, Symphogen, Intensity Therapeutics, Mirati Therapeutics, Shattucks, and Avid Therapeutics outside the submitted work. A.R. Hansen reports grants and other support from Merck and GSK; other support from Eisai; and grants from Genentech, Roche, BMS, Astellas, AstraZeneca, Janssen, Bayer, and Boehringer Ingelheim outside the submitted work. No disclosures were reported by the other authors.

References

- Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. *Nat Rev Drug Discov* 2009;8:627–44.
- Vanhaesebroeck B, Stephens L, Hawkins P. PI3K signalling: the path to discovery and understanding. *Nat Rev Mol Cell Biol* 2012;13:195–203.
- Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, et al. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. *Nature* 2008;454:776–9.
- Jean S, Kiger AA. Classes of phosphoinositide 3-kinases at a glance. *J Cell Sci* 2014;127:923–8.
- Tzenaki N, Papakonstanti EA. p110delta PI3 kinase pathway: emerging roles in cancer. *Front Oncol* 2013;3:40.
- Falasca M, Maffucci T. Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts. *Front Physiol* 2014;5:391.
- Ni J, Liu Q, Xie S, Carlson C, Von T, Vogel K, et al. Functional characterization of an isoform-selective inhibitor of PI3K-p110beta as a potential anticancer agent. *Cancer Discov* 2012;2:425–33.
- Wee S, Wiederschain D, Maira SM, Loo A, Miller C, deBeaumont R, et al. PTEN-deficient cancers depend on PIK3CB. *Proc Natl Acad Sci U S A* 2008;105:13057–62.
- Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. *Cell* 2008;133:403–14.
- Hancox U, Cosulich S, Hanson L, Trigwell C, Lenaghan C, Ellston R, et al. Inhibition of PI3Kbeta signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel. *Mol Cancer Ther* 2015;14:48–58.
- Barlaam B, Cosulich S, Degorce S, Fitzek M, Green S, Hancox U, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3Kbeta and PI3Kdelta for the treatment of PTEN-deficient cancers. *J Med Chem* 2015;58:943–62.
- Lynch JT, Polanska UM, Hancox U, Delpuech O, Maynard J, Trigwell C, et al. Combined inhibition of PI3Kbeta and mTOR inhibits growth of PTEN-null tumors. *Mol Cancer Ther* 2018;17:2309–19.

Authors' Contributions

A.D. Choudhury: Formal analysis, writing—original draft, writing—review and editing. **C.S. Higo:** Formal analysis, writing—original draft, writing—review and editing. **J.S. de Bono:** Formal analysis, writing—original draft, writing—review and editing. **N. Cook:** Formal analysis, writing—original draft, writing—review and editing. **D.E. Rathkopf:** Formal analysis, writing—original draft, writing—review and editing. **K.B. Wisinski:** Formal analysis, writing—original draft, writing—review and editing. **J. Martin-Liberal:** Formal analysis, funding acquisition, writing—original draft, writing—review and editing. **M. Linch:** Formal analysis, writing—original draft, writing—review and editing. **E.I. Heath:** Formal analysis, writing—original draft, writing—review and editing. **R.D. Baird:** Formal analysis, writing—original draft, writing—review and editing. **J. Garcia-Carbacho:** Formal analysis, writing—original draft, writing—review and editing. **M. Quintela-Fandino:** Formal analysis, writing—original draft, writing—review and editing. **S.T. Barry:** Conceptualization, formal analysis, supervision, writing—original draft, writing—review and editing. **E.C. de Bruin:** Formal analysis, writing—original draft, writing—review and editing. **S. Colebrook:** Conceptualization, formal analysis, supervision, writing—original draft, writing—review and editing. **G. Hawkins:** Formal analysis, writing—original draft, writing—review and editing. **T. Klinowska:** Conceptualization, formal analysis, supervision, writing—original draft, writing—review and editing. **B. Maroj:** Formal analysis, writing—original draft, writing—review and editing. **G. Moorthy:** Formal analysis, writing—original draft, writing—review and editing. **P.G. Mortimer:** Formal analysis, writing—original draft, writing—review and editing. **M. Moschetta:** Conceptualization, formal analysis, supervision, writing—original draft, writing—review and editing. **M. Nikolaou:** Formal analysis, writing—original draft, writing—review and editing. **L. Sainsbury:** Formal analysis, writing—original draft, writing—review and editing. **G.I. Shapiro:** Formal analysis, writing—original draft, writing—review and editing. **L.L. Siu:** Formal analysis, writing—original draft, writing—review and editing. **A.R. Hansen:** Formal analysis, writing—original draft, writing—review and editing.

Acknowledgments

This study was sponsored by AstraZeneca. We thank the patients and their doctors and caregivers who participated in this study. We acknowledge support in Cambridge from Cancer Research UK, Experimental Cancer Medicine Center, NIHR Biomedical Research Center, and NIHR Cambridge Clinical Research Center. Research at the Christie NHS Foundation Trust was supported by the NIHR Manchester Clinical Research Facility and Manchester Experimental Cancer Medicine Center award. We also thank Martine Roudier (AstraZeneca) for providing analysis data of tumor tissue biopsies, and Wolfram Brugger and Caroline Kennedy (AstraZeneca, Cambridge, UK). Abiraterone acetate was kindly provided by Janssen. Medical writing and editorial assistance were provided by Bioscript Medical, Macclesfield, UK, and funded by AstraZeneca.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received August 27, 2021; revised December 21, 2021; accepted March 1, 2022; published first March 4, 2022.

13. Marques RB, Aghai A, de Ridder CMA, Stuurman D, Hoeben S, Boer A, et al. High efficacy of combination therapy using PI3K/AKT inhibitors with androgen deprivation in prostate cancer preclinical models. *Eur Urol* 2015;67:1177–85.
14. Schwartz S, Wongvipat J, Trigwell CB, Hancox U, Carver BS, Rodrik-Outmezguine V, et al. Feedback suppression of PI3K α signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3K β . *Cancer Cell* 2015;27:109–22.
15. Ferraldeschi R, Nava Rodrigues D, Riisnaes R, Miranda S, Figueiredo I, Rescigno P, et al. PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. *Eur Urol* 2015;67:795–802.
16. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. *JAMA* 2013;310:2191–4.
17. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer* 2009;45:228–47.
18. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate-specific antigen working group. *J Clin Oncol* 1999;17:3461–7.
19. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. *J Clin Oncol* 2008;26:1148–59.
20. de Bono JS, Fleming MT, Wang JS, Cathomas R, Miralles MS, Bothos J, et al. Phase I study of MEDI3726: a prostate-specific membrane antigen-targeted antibody–drug conjugate, in patients with mCRPC after failure of abiraterone or enzalutamide. *Clin Cancer Res* 2021;27:3602–9.
21. Elvin P, Palmer A, Womack C, Tall M, Swales KE, Garrett MD, et al. Pharmacodynamic activity of the AKT inhibitor AZD5363 in patients with advanced solid tumors. *J Clin Oncol* 2014;32:2541.
22. Ebner M, Lucic I, Leonard TA, Yudushkin I. PI(3,4,5)P $_3$ engagement restricts Akt activity to cellular membranes. *Mol Cell* 2017;65:416–31.
23. Manning BD, Toker A. AKT/PKB signaling: navigating the network. *Cell* 2017;169:381–405.
24. FDA. ALIQOPA (copanlisib). Highlights of Prescribing Information. 2017. [cited 2021 Nov]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209936s000lbl.pdf.
25. FDA. ZYDELIG[®] (idelalisib). Highlights of Prescribing Information. 2020. [cited 2021 Nov]. Available from: https://www.gilead.com/-/media/files/pdfs/medicines/oncology/zydelig/zydelig_pi.pdf.
26. Munoz J, Follows GA, Nastoupil LJ. Copanlisib for the treatment of malignant lymphoma: clinical experience and future perspectives. *Target Oncol* 2021;16:295–308.
27. Gilead Sciences. Zydelig (idelalisib) 100 mg and 150 mg tablets. Adverse event monitoring and management. 2020. [cited 2021 Nov]. Available from: <https://www.zydelig.com/hcp/adverse-event-management>.
28. Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birtle D, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. *J Clin Oncol* 2012;30:282–90.
29. Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. *Annu Rev Pathol* 2009;4:127–50.
30. Mazumdar T, Byers LA, Ng PK, Mills GB, Peng S, Diao L, et al. A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma. *Mol Cancer Ther* 2014;13:2738–50.
31. Shepherd C, Banerjee L, Cheung CW, Mansour MR, Jenkinson S, Gale RE, et al. PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response. *Leukemia* 2013;27:650–60.
32. Mateo J, Ganji G, Lemech C, Burris HA, Han SW, Swales K, et al. A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors. *Clin Cancer Res* 2017;23:5981–92.
33. Nastoupil LJ, Neelapu SS, Davis E, Samaniego F, Fowler NH, Westin JR, et al. Results of a first in human, dose ascending, phase I study examining the safety and tolerability of KA2237, an oral PI3K p110 β / δ inhibitor in patients with relapsed/refractory (R/R) B-cell lymphoma. *Blood* 2019;134:4099.
34. O'Donnell JS, Massi D, Teng MWL, Mandala M. PI3K–AKT–mTOR inhibition in cancer immunotherapy, redux. *Semin Cancer Biol* 2018;48:91–103.
35. Juric D, Castel P, Griffith M, Griffith OL, Won HH, Ellis H, et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)K α inhibitor. *Nature* 2015;518:240–4.